Visualization analysis in studies of peptic ulcer based on Citespace software

YANG Kun; GAN Lihua; GUO Chaofeng

doi:10.7619/jcmp.20201499

Journal of Clinical Medicine in Practice > 2021 > 25(5): 1-6. > DOI: 10.7619/jcmp.20201499

YANG Kun, GAN Lihua, GUO Chaofeng. Visualization analysis in studies of peptic ulcer based on Citespace software[J]. Journal of Clinical Medicine in Practice, 2021, 25(5): 1-6. DOI: 10.7619/jcmp.20201499

Citation:

PDF (2932 KB)

Visualization analysis in studies of peptic ulcer based on Citespace software

1.
Graduate School, Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, 530001
2.
First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine, Nanning, Guangxi, 530023

More Information

Received Date: November 20, 2020
Available Online: March 22, 2021
Published Date: March 14, 2021

Graphical Abstract

Abstract

Abstract

Objective To analyze the research hotspots and development trend of peptic ulcer (PU) from 2010 to 2019.
Methods Relevant literatures on PU were retrieved from the Web of Science, and visualization analysis map was obtained with the help of analysis by the visual software Citespace.
Results A total of 4 317 relevant literatures were retrieved, and the highest number of articles published was found in 2014. The results showed that YOSHIO YAMAOKA was the main researcher, who published 23 relevant literatures. The country with the largest number of published literatures was the United States, and the organization with the largest number of published literatures was Yangming University in Taiwan. The most cited journal was Gastroenterology. A total of 158 key words were included, among which "Helicobacter pylori" "infection" and "management" were the main key words.
Conclusion With the help of visualization analysis in PU by Citespace software, we can easily and conveniently understand the research hotspots and development trend of treatments for PU.
- Citespace,
- peptic ulcer,
- development trends,
- research hotspots

FullText(HTML)

References (20)

References

[1]	BARKUN A N, BARDOU M, KUIPERS E J, et al. International consensus recommendations on the management of patients with nonvariceal upper gastrointestinal bleeding[J]. Ann Intern Med, 2010, 152(2): 101-113. doi: 10.7326/0003-4819-152-2-201001190-00009
[2]	LANAS A, CHAN F K L. Peptic ulcer disease[J]. Lancet, 2017, 390(10094): 613-624. doi: 10.1016/S0140-6736(16)32404-7
[3]	NARAYANAN M, REDDY K M, MARSICANO E. Peptic Ulcer Disease and Helicobacter pylori infection[J]. Mo Med, 2018, 115(3): 219-224.
[4]	MALFERTHEINER P, CHAN F K, MCCOLL K E. Peptic ulcer disease[J]. Lancet, 2009, 374(9699): 1449-1461. doi: 10.1016/S0140-6736(09)60938-7
[5]	MALFERTHEINER P, BAZZOLI F, DELCHIER J C, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial[J]. Lancet, 2011, 377(9769): 905-913. doi: 10.1016/S0140-6736(11)60020-2
[6]	MATSUO Y, KIDO Y, YAMAOKA Y. Helicobacter pylori outer membrane protein-related pathogenesis[J]. Toxins (Basel), 2017, 9(3): E101. doi: 10.3390/toxins9030101
[7]	SUNG J J Y, TSOI K K, MA T K, et al. Causes of mortality in patients with peptic ulcer bleeding: a prospective cohort study of 10, 428 cases[J]. Am J Gastroenterol, 2010, 105(1): 84-89. doi: 10.1038/ajg.2009.507
[8]	LAINE L, JENSEN D M. Management of patients with ulcer bleeding[J]. Am J Gastroenterol, 2012, 107(3): 345-361. doi: 10.1038/ajg.2011.480
[9]	BHATT D L, CRYER B L, CONTANT C F, et al. Clopidogrel with or without omeprazole in coronary artery disease[J]. N Engl J Med, 2010, 363(20): 1909-1917. doi: 10.1056/NEJMoa1007964
[10]	LAU J Y, BARKUN A, FAN D M, et al. Challenges in the management of acute peptic ulcer bleeding[J]. Lancet, 2013, 381(9882): 2033-2043. doi: 10.1016/S0140-6736(13)60596-6
[11]	HEARNSHAW S A, LOGAN R F, LOWE D, et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit[J]. Gut, 2011, 60(10): 1327-1335. doi: 10.1136/gut.2010.228437
[12]	WANG Y R, RICHTER J E, DEMPSEY D T. Trends and outcomes of hospitalizations for peptic ulcer disease in the United States, 1993 to 2006[J]. Ann Surg, 2010, 251(1): 51-58. doi: 10.1097/SLA.0b013e3181b975b8
[13]	FUKASE K, KATO M, KIKUCHI S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial[J]. Lancet, 2008, 372(9636): 392-397. doi: 10.1016/S0140-6736(08)61159-9
[14]	EUSEBI L H, ZAGARI R M, BAZZOLI F. Epidemiology of Helicobacter pylori infection[J]. Helicobacter, 2014, 19(Suppl 1): 1-5. http://epirev.oxfordjournals.org/content/13/1/42.full.pdf+html
[15]	SIVARAM P, SREEKUMAR A. Preoperative factors influencing mortality and morbidity in peptic ulcer perforation[J]. Eur J Trauma Emerg Surg, 2018, 44(2): 251-257. doi: 10.1007/s00068-017-0777-7
[16]	KINOSHITA Y, ISHIMURA N, ISHIHARA S. Advantages and disadvantages of long-term proton pump inhibitor use[J]. J Neurogastroenterol Motil, 2018, 24(2): 182-196. doi: 10.5056/jnm18001
[17]	NAJM W I. Peptic ulcer disease[J]. Prim Care: Clin Off Pract, 2011, 38(3): 383-394. doi: 10.1016/j.pop.2011.05.001
[18]	DE CÁSSIA DOS SANTOS R, BONAMIN F, PÉRICO L L, et al. Byrsonima intermedia A. Juss partitions promote gastroprotection against peptic ulcers and improve healing through antioxidant and anti-inflammatory activities[J]. Biomedecine Pharmacother, 2019, 111: 1112-1123. doi: 10.1016/j.biopha.2018.12.132
[19]	YIP H C, TEOH A Y B. Importance of timely eradication of Helicobacter pylori to prevent peptic ulcer recurrence and gastric cancer[J]. Gastrointest Endosc, 2018, 88(2): 251-252. doi: 10.1016/j.gie.2018.03.016
[20]	PAN W, ZHANG H, WANG L, et al. Association between Helicobacter pylori infection and kidney damage in patients with peptic ulcer[J]. Ren Fail, 2019, 41(1): 1028-1034. doi: 10.1080/0886022X.2019.1683029

[1]	YU Fulin, HUANG Jiangbo, NING Yangshan. Correlations of serum phosphoglycerate mutase family member 5 and YT521-B homology N6-methyladenosine RNA binding protein 2 levels with ventricular remodeling and prognosis in patients with heart failure with preserved ejection fraction[J]. Journal of Clinical Medicine in Practice, 2025, 29(5): 64-69. DOI: 10.7619/jcmp.20244630
[2]	Gulimila ·ABUDUKAHA, LI Yatan, YANG Fan. Regulation of atorvastatin on the Hippo-YAP signaling pathway in rats with chronic heart failure and its impact on ventricular remodeling[J]. Journal of Clinical Medicine in Practice, 2024, 28(22): 55-61. DOI: 10.7619/jcmp.20241911
[3]	YANG Rui, YU Junmin, ZHANG Xiaobo, LI Dahe, ZHAO Yuanyuan, CHEN Hongye. Research progress on molecular mechanism related to ventricular remodeling in elderly patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2023, 27(23): 139-143. DOI: 10.7619/jcmp.20231891
[4]	YAO Dan, ZHENG Ju, PANG Chong, WU Yanming, YOU Hua. Effect of sacubitril/valsartan on echocardiographic parameters in patients with chronic heart failure with reduced ejection fraction[J]. Journal of Clinical Medicine in Practice, 2021, 25(7): 81-84, 88. DOI: 10.7619/jcmp.20210125
[5]	QIU Qingyan, DAI Min, MOU Ying, YU Hui. Effect of metoprolol combined with trimetazidine on serum angiotensin Ⅱ and vascular endothelial function in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2021, 25(3): 99-102, 106. DOI: 10.7619/jcmp.20200912
[6]	WANG Juping, YANG Weilun, SHI Le. Pharmacological mechanism and research progress of traditional Chinese medicine in the treatment of chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 125-128. DOI: 10.7619/jcmp.202012035
[7]	TANG Yong, LU Yong. Clinical effect of Qili Qiangxin Capsule combined with nicorandil in treatment of chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 35-38. DOI: 10.7619/jcmp.202012010
[8]	ZHANG Liwei. Correlations between serum uric acid, N-terminal pro-B-type natriuretic peptide, vasostatin-2 and left ventricular ejection fraction in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2020, 24(12): 29-31. DOI: 10.7619/jcmp.202012008
[9]	TANG Yuanyuan, HOU Xiaofeng, WANG Yao, ZOU Jiangang. Correlation between serum N-terminal pro-brain natriuretic peptide, serum cystatin C and left ventricular remodeling in patients with chronic heart failure[J]. Journal of Clinical Medicine in Practice, 2015, (24): 59-62. DOI: 10.7619/jcmp.201524018
[10]	HU Huan, WANG Xiang. Correlation between plasma brain natriuretic peptide and left ventricular remodeling[J]. Journal of Clinical Medicine in Practice, 2013, (21): 19-23. DOI: 10.7619/jcmp.201321006

Cited By

Get Citation

PDF

XML

Article views (395) PDF downloads (46)

Turn off MathJax

Article Contents

Abstract

References

Visualization analysis in studies of peptic ulcer based on Citespace software

Abstract

References

Related Articles

Catalog

Visualization analysis in studies of peptic ulcer based on Citespace software

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content